GRDN
Guardian Pharmacy Services, Inc.
Next earnings Aug 10, 2026 · consensus $0.28 EPS, $347M rev
Last earnings -1.8% on 2026-05-06
$42.31
▲ +8.82%$42.31▲ +110.50%
over 1Y
L $19.97EODHDH $43.40
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+8.8%
1W+8.8%
1M+8.2%
3M+23.9%
YTD+43.3%
1Y+110.5%
Buy
Conviction
Horizon
Medium (3–12mo)
Street · 12 analysts
Strong Buy
Revenue grew 17.9% YoY.
Guardian Pharmacy Services, Inc. shows $1.45B in FY2025 revenue (+17.9% YoY), a 3.4% net margin, and 22.6% ROE.
Financials · annual, by fiscal year
| Line item | FY24 | FY25 |
|---|---|---|
| Revenue | $1.23B | $1.45B |
| Gross profit | $244M | $293M |
| Operating income | -$62.9M | $72.7M |
| Net income | -$110M | $49.2M |
| Diluted EPS | — | — |
| Net margin | -9.0% | 3.4% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value—
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield—
FCF yield—
Quality & risk
ROIC (est.)26.4%
Free cash flow$86.8M
Total debt$0.00
Net cash$65.6M
Piotroski F-Score7/8
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-06-222026-06-22open ↗8-KPeriod ending 2026-05-212026-05-28open ↗4Period ending 2026-05-052026-05-07open ↗4Period ending 2026-05-052026-05-07open ↗4Period ending 2026-05-052026-05-07open ↗8-KPeriod ending 2026-05-052026-05-07open ↗S-8Filing2026-05-06open ↗S-3ASRFiling2026-05-06open ↗10-QPeriod ending 2026-03-312026-05-06open ↗8-KPeriod ending 2026-05-062026-05-06open ↗SCHEDULE 13GFiling2026-05-06open ↗3Period ending 2026-04-012026-04-13open ↗
Frequently asked
- Is Guardian Pharmacy Services, Inc. (GRDN) a buy?
- GRDN currently carries a Buy rating with 4/5 conviction, derived from its latest SEC filings. Revenue grew 17.9% YoY.
- What is Guardian Pharmacy Services, Inc.'s quality score?
- GRDN scores 76.28205128205127/100 (grade B+) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001802255, latest 10-Q filed 2026-05-06) · EODHD · as of 6/27/2026, 7:54:35 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.